Keyphrases
Human Epidermal Growth Factor Receptor 2 (HER2)
100%
Metastatic Breast Cancer
100%
Cost-effectiveness Analysis
100%
Fluorescence in Situ Hybridization
100%
Trastuzumab Therapy
100%
Incremental Cost-effectiveness Ratio
80%
HercepTest
80%
Trastuzumab
60%
Quality-adjusted Life Years
60%
Life-years Gained
40%
Test Characteristics
40%
Cost-effectiveness
20%
Tumor
20%
Treatment Strategy
20%
Chemotherapy
20%
Clinical Practice
20%
Treatment Efficacy
20%
Decision Analysis
20%
Chemotherapy Alone
20%
Treatment Costs
20%
High Cost
20%
Protein-coding Genes
20%
OR Genes
20%
Protein Overexpression
20%
Gene Amplification
20%
Lifetime Cost
20%
Immunohistochemical Assay
20%
Multiple Tests
20%
Weakly Positive
20%
State Transition Model
20%
Positive Check
20%
Treatment Candidates
20%
Negative Test Results
20%
Aggregate Cost
20%
Nursing and Health Professions
Cost Effectiveness Analysis
100%
Metastatic Breast Cancer
100%
Fluorescence in Situ Hybridization
100%
Trastuzumab
100%
HER2 Protein Detection Kit
80%
Quality Adjusted Life Year
60%
Incremental Cost-Effectiveness Ratio
60%
Clinical Practice
20%
Epidermal Growth Factor Receptor 2
20%
Base
20%
Neoplasm
20%
Biochemistry, Genetics and Molecular Biology
Fluorescence in Situ Hybridization
100%
Trastuzumab
100%
Quality Adjusted Life Year
60%
Lifespan
20%
Gene Amplification
20%